(509) 228-1000 WA
(208) 754-3100 ID

Coronavirus (COVID-19) Update: Get the latest information on how we’re responding to the novel coronavirus (COVID-19). CLICK HERE »

Hakan Kaya, MD

Share

back to doctors

Specialty

Autologous Stem Cell Transplantation

Medical Oncology and Hematology

Location:

SOUTH SPOKANE

Additional Areas of Expertise:

Multiple Myeloma, Lymphoma

 

  • Oncologist/Hematologist and Senior Partner, Cancer Care Northwest
  • Director, Inland Northwest Myeloma/Lymphoma & Transplant Program
  • Clinical Professor, Elson S. Floyd College of Medicine Washington State University
  • Clinical Professor of Medicine, University of Washington School of Medicine
 
Dr. Hakan Kaya has been practicing hematology/oncology in Spokane since 2001. He joined Cancer Care Northwest in 2004 with a goal of forming the first and the only autologous stem cell transplantation program in the Inland Northwest. He is a fellowship-trained transplant physician who specializes in Multiple Myeloma and B-cell Lymphomas.  He is the Founding Director of the Inland Northwest Myeloma/Lymphoma and Transplant Program, established in 2005. In addition to autologous stem cell transplantation, he offers the latest treatment options to Multiple Myeloma and B-cell Lymphoma patients who live in Eastern Washington, North Idaho and Western Montana. 
 
Dr. Kaya has been teaching residents, interns, and students of this medical community for nearly two decades. He is a Clinical Professor at Elson S. Floyd College of Medicine Washington State University, where he has been active in developing and teaching a formal hematology/oncology course to first year medical students. He is also a Clinical Professor of Medicine at the University Of Washington School Of Medicine. 
 
Outside of work, Dr. Kaya spends most of his time with family activities. He also enjoys practicing martial arts (World Taekwondo Federation certified 1st Degree Black Belt) which helps him to cope with daily stresses of being a cancer doctor.

 

Education

Medical School:

  • Ankara University School of Medicine; Ankara, Turkey

Residency & Internship:

  • University of Oklahoma Health Sciences Center (Internal Medicine); Oklahoma City, OK

Fellowship:

  •  Comprehensive Cancer Center of Wake Forest University (Medical Oncology, Hematology, and Bone Marrow Transplantation); Winston-Salem, NC
    (Three year fellowship training in Medical Oncology, Hematology, and Bone Marrow Transplantation. His fellowship included a one-year program entitled "Specialized Training in Hematopoietic Stem Cell Transplantation" which was designed to fulfill the guidelines for training (BMT fellowship) adopted by the American Society of Blood and Marrow Transplantation)

Current Acedemic Positions:

  • Clinical Professor, Elson S. Floyd College of Medicine, Washington State University
  • Clinical Professor, University of Washington School of Medicine

Certification
  •  American Board of Internal Medicine: Medical Oncology

 

Honors & Awards
  • Founder and Director of the Inland Northwest Myeloma/Lymphoma and Transplant Program 
  • Best Doctors in America® list, specialty Medical Oncology & Hematology, 2015-2019
  • Recipient of Outstanding Clinical Faculty Award for 2006-2007 by Internal Medicine Residency Spokane
  • Recipient of the Assembly of Turkish American Associations (ATAA) 2004 Outstanding Achievement in the Arts/Sciences Award
  • Recipient of Chief Residents’ Award for Outstanding Service to the Residency Program, University of Oklahoma
  • Recipient of Best Poster Presentation Award at the Department of Medicine House Staff Research Day, University of Oklahoma, Department of Medicine
  • Recipient of Special Recognition Award in Poster Presentation in allogeneic bone marrow transplantation at the American College of Physicians-Oklahoma Chapter Annual Meeting
  • Best Student Research Award in Basic Sciences, Ankara University School of Medicine    
  • Scored among the top 0.1 % students out of 500,000 examiners who took the university admission test in 1986 in Turkey

 

In the local media

 

Multiple Myeloma Presentations at Recent International Meetings
  • European Hematology Association 2018 annual meeting; Stockholm, Sweden (June 2018)
    Nizar J Bahlis, Gary J Schiller, Kevin Song, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, Christy Samaras, Ehsan Malek, Giampaolo Talamo, Christopher S Seet, Jorge Mouro, Faiza Zafar, Weiyuan Chung, Shankar Srinivasan, Max Qian, Amit Agarwal, Anjan Thakurta, David S Siegel. 
    Safety and efficacy of Pomalidomide + Low-Dose Dexamethasone immediately following lenalidomide-based treatment failure in patients with relapses and/or refractory Multiple Myeloma. 
  • Japanese Society of Myeloma (JSM) 2018 annual meeting; Tokyo, Japan (May 2018)
    Nizar J Bahlis, Gary J Schiller, Kevin Song, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, Christy Samaras, Ehsan Malek, Giampaolo Talamo, Christopher S Seet, Jorge Mouro, Faiza Zafar, Weiyuan Chung, Shankar Srinivasan, Max Qian, Amit Agarwal, Anjan Thakurta, David S Siegel.
    Pomalidomide + Low-Dose Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM). 
  • American Society of Hematology (ASH) Annual Meeting (December 2017)
    David Siegel, Gary J. Schiller, Kevin W Song, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, Christy Samaras, Ehsan Malek, Giampaolo Talamo, Christopher Seet, Jorge Mouro, Faiza Zafar, Weiyuan Chung, Shankar Srinivasan, Max Qian, Amit Agarwal, Anjan Thakurta and Nizar J. Bahlis.
    Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed.
  • American Society of Clinical Oncology (ASCO) Annual Meeting (June 2017)
    David Siegel, Gary J. Schiller, Kevin W. Song, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, Frederic J. Reu, Ehsan Malek, Giampaolo Talamo, Jorge L Mouro, Weiyuan Chung, Shankar Srinivasan, Max Qian, Syed Rizvi, Anjan Thakurta, Nizar J. Bahlis.
    Pomalidomide (POM) + low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control. 
  • American Society of Hematology (ASH) Annual Meeting (December 2016)
    David S. Siegel, Gary J. Schiller, Kevin W. Song, Richy Agajanian, Keith Stockerl- Goldstein, Hakan Kaya, MichaelSebag, Fred. Reu, Ehsan Malek, Jorge Mouro, Weiyuan Chung, Shankar Srinivasan, Max Qian, Syed Rizvi, AnjanThakurta and Nizar J. Bahlis.
    Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety. 
  • American Society of Hematology (ASH) Annual Meeting (December 2015)
    DavidSiegel, Gary Schiller, Kevin Song, Richy Agajanian, Keith StockerlGoldstein, Hakan Kaya, Michael Sebag, FredericJ Reu, Jorge Mouro, Michael Sturniolo, Shankar Srinivasan, Anjan Thakurta, Yasir Nagarwala and Nizar JBahlis.
    Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM). 
  • American Society of Clinical Oncology (ASCO) Annual Meeting (June 2014)
    David Siegel, Richy Agajanian, Rakesh Gaur, Kasra Karamlou, Hakan Kaya, Michael Sturniolo, Rosanna J. Ricafort, Gail Larkins, Shankar Srinivasan, Rajesh Chopra, Anjan Thakurta, Yasir M. Nagarwala, Flavio Kruter.
    MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN + DEX). 
  • American Society of Hematology (ASH) Annual Meeting (December 2013)
    PaulG. Richardson, Arnon Nagler, Dina BenYehuda, Ashraf Badros, Yehuda, Ashraf Badros, Parameswaran Hari, Roman Hajek, IvanSpicka, Hakan Kaya, Kenneth C. Anderson.
    Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib. 
  • American Society of Hematology (ASH) Annual Meeting (December 2013)
    Ravi Vij, MehdiM. Moezi, Robin Foà, Gordon Cook, Antonio Palumbo, Hakan Kaya, Brian Durie, David Cella, LievenAnnemans, Yun Su, Pralay Mukhopadhyay, TrongK. Le and MariaTeresa Petrucci.
    A New Multi-national Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study. 
  • American Society of Hematology (ASH) Annual Meeting (December 2012)
    Vikram Dhillon, Danko Martincic, ChristopherM Lee, Ndegwa Njuguna, David Schmick, Annette Nagle, Rachel LGarman and Hakan Kaya.
    Multiple Myeloma Care in the Community Setting by Utilizing Progressive Clinical Care Pathways.
  • American Society of Hematology (ASH) Annual Meeting (December 2011)
    Hakan Kaya, Danko Martincic, Irfan Jawed, Ben Peressini, Ameer L Elaimy and Christopher M Lee.
    A Critical Population Analysis of 57, 500 US Multiple Myeloma Patients: Impact of Race, Age, and Decade of Treatment on Overall Survival.

Peer Reviewed Articles